Skip to main content
SpringerLink
Log in

Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain

  • Published:
European Journal of Epidemiology Aims and scope Submit manuscript

Abstract

Injection drug use (IDU) is one of the most significant risk factors for viral hepatitis (B, D and C) and human immunodeficiency virus (HIV) infection. However, there is little information about the risk of infection among non-injection drug users (non-IDUs). The present study was designed to perform several objectives: (a) to evaluate the prevalence of serological markers of hepatitis B, D, C virus and HIV in IDU and non-IDU patients; (b) to compare the prevalence of these markers between both groups; (c) to identify risk factors for HCV and HIV in this population; and (d) to correlate the presence of HCV and liver function. A total of 385 consecutive patients (122 IDUs and 263 non-IDUs), admitted to the Drug Dependency Treatment Unit at the Hospital Insular of Gran Canaria between 1993 to 1994, were included in the study. The serological markers of HBV, HDV, HCV and HIV were determined by ELISA and immunoblot methods. In all cases we also measured syphilis tests (RPR and FTAabs), serum aminotransferases and serum gammaglutamiltranspeptidase. Compared to the non-IDU, the IDU group presents a higher prevalence of antiHBc (55.0% vs. 20.7%, p < 0.0001), antiHCV (87.6% vs. 35.3%, p < 0.0001) and antiHIV (21.8% vs. 2.7%, p < 0.0001). There was no significant difference in RPR positivity (0.9% vs. 4.9%, p = 0.06). Delta infection was only detected in injection drug users, and the prevalence was low. Using logistic regression, the only risk factors associated with antiHCV positivity were injection drug addiction (OR: 9.2, 95% CI: 4.9–17.0) and antiHBc positivity (OR: 5.5, 95% CI: 3.0–9.9). Similarly, the associated risk factors for HIV were injection drug addiction (OR: 5.9, 95% CI: 2.3–15.0) and antiHBc positivity (OR: 3.8, 95% CI: 1.5–9.2). However, no correlation was found between antiHCV positive and antiHIV or between these markers and RPR positivity. Patients positive for antiHCV showed significant elevations in aspartate aminotransferase and alanine aminotransferase levels, when compared with patients negative for antiHCV: 65.0 vs. 39.2 U.l (p < 0.001) and 88.4 vs. 40.3 U/l (p < 0.001), respectively. We conclude that drug users have an elevated prevalence of HCV, HBV and HIV infection, even if drug use is only inhalated. On the other hand, the main risk factors associated with HCV and HIV are injection drug addiction and exposure to hepatitis B virus. Finally, in the study population, liver dysfunction is closely related to HCV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Huemer HP, Prodinger WM, Larcher C, Most J, Dierich MP, Correlation of hepatitis C virus antibodies with HIV-1 seropositivity in intravenous drug addicts. Infection 1990; 18: 122–123.

    PubMed  Google Scholar 

  2. Van Ameijden EJC, van den Hoek JAR, Mientjes GHC, Coutinho RA. A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993; 9: 255–262.

    PubMed  Google Scholar 

  3. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R, Nelson KE. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74: 212–220.

    Article  Google Scholar 

  4. Fingerhood MI, Jasinski DR, Sullivan JT. Prevalence of hepatitis C in a chemically dependent population. Arch Intern Med 1993; 153: 2025–2030.

    Article  PubMed  Google Scholar 

  5. Lissen E, Alter HJ, Abad MA, Torres Y, Pérez-Romero M, Leal M, Pineda JA, Torronteras R, Sánchez-Quijano A. Hepatitis C virus infection among sexually promiscuous groups and the heterosexual partners of hepatitis C virus infected index cases. Eur J Clin Microbiol Infect Dis 1993; 12: 827–831.

    PubMed  Google Scholar 

  6. Martín P, Dibisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JH. Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. Gastroenterol 1989; 97: 1559–1561.

    Google Scholar 

  7. Esteban JI, Esteban R, Viladomiu L, López Talavera JC, González A, Hernández JM, Roget M, Vargas V, Genesca J, Buti M, Guardia J, Houghton M, Choo QL, Kuo G. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989; 2: 294–297.

    Article  PubMed  Google Scholar 

  8. Martínez JL, del Hierro J, Camarero A, Medarde A, López MT, Latasa J. Estudio de la infección por virus de la hepatitis C en diferentes grupos de riesgo y en donantes de sangre. Enferm Infecc Microbiol Clin 1991; 9: 345–348.

    PubMed  Google Scholar 

  9. Santana OE, Francés A, Sierra A, Hernández J, Martín-Sánchez AM. Marcadores serológicos de hepatitis B: Patrones atípicos detectados en el Hospital Insular de Gran Canaria. Rev Clin Esp 1995; 195: 674–677.

    PubMed  Google Scholar 

  10. Lucidarme D, Foutrein Ph, Creusy C, Forzy G, Foutrein-Comes MC, Muyssen A, Baylly D, Parquet PhJ, Filoche B. Prèvalence des marqueurs des hépatites C, B et D et aspects histopathologiques dans un groupe de toxicomanes intraveineux. Gastroenterol Clin Biol 1994; 18: 964–968.

    PubMed  Google Scholar 

  11. Francisci D, Baldelli F, Papili R, Stagni G, Pauluzzi S. Prevalence of HBV, HDV and HCV hepatitis markers in HIV-positive patients. Eur J Epidemiol 1995; 11: 123–126.

    PubMed  Google Scholar 

  12. Tennant F, Covina W. Hepatitis C in intravenous drug addicts. Arch Intern Med 1994; 154: 1163–1164.

    Article  Google Scholar 

  13. Echevarría S, San Miguel G, Pelayo T, Salas C, Casafont F, Crespo J, Pons Romero F. Importancia de la transmisión sexual del VHB y VHC. Estudio en prostitutas. Gastroenterol Hepatol 1993; 16: 425–428.

    Google Scholar 

  14. Hernández ME, Bruguera M, Puyuelo T, Barrera JM, Sánchez Tapias JM, Rodés J. Risk of needle-stick injuries in the transmission of hepatitis C virus in hospital personnel. J Hepatol 1992; 16: 56–58.

    PubMed  Google Scholar 

  15. Zuckerman J, Clewley G, Griffiths P, Cock Croft A. Prevalence of hepatitis C antibodies in clinical health care workers. Lancet 1994; 343: 1618–1620.

    Article  PubMed  Google Scholar 

  16. Rumi GM, Colombo M, Gringeri A, Mannucci PM. High prevalence of antibody to hepatitis C virus in multitransfused hemophiliacs with normal transaminase levels. Ann Intern Med 1990; 112: 379–380.

    PubMed  Google Scholar 

  17. Conry-Cantilena C, Van Raden M, Gibble J, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691–1696.

    Article  PubMed  Google Scholar 

  18. Camps J, Esteban R. Hepatitis C. Enferm Infecc Microbiol Clin 1995; 13(suppl): 31–39.

    PubMed  Google Scholar 

  19. Sacristán B, Castañares MJ, Elena A, Sacristán M, Barcenilla J, García JC, Yangüela J. Infección por el virus de la hepatitis C. Estudio seroepidemiológico en población general de La Rioja. Med Clin (Barc) 1996; 107: 331–335.

    Google Scholar 

  20. Hallam NF, Fletcher ML, Read SJ, Majid AM, Kurtz JB, Rizza CR. low risk of sexual transmission of hepatitis C virus. J Med Virol 1993; 40: 251–253.

    PubMed  Google Scholar 

  21. Morales MA, Pineda JA, Leal M, Pino R, Torronteras R, Sánchez-Quijano A, Lissen E. Prevalencia de anticuerpos frente al virus de la hepatitis C en un colectivo de varones homosexuales. Med Clin (Barc) 1993; 100: 50–52.

    Google Scholar 

  22. Farci P, Alter H, Wong D, Miller R, Shih J, Jett B, Purcell H. A long-term study of hepatitic C virus replication in non-A, non-B hepatitis. N Engl J Med 1991; 325: 98–104.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Microbiology Service, Spain

    Otilia Evora Santana Rodríguez, María Luisa Malé Gil & Antonio Manuel Martín Sánchez

  2. Drug Dependency Treatment Unit, Spain

    Juan Francisco Hernández Santana

  3. Biostatistic Unit, Hospital Insular de Gran Canaria, Health Sciences Center, Universidad de Las Palmas de Gran Canaria, Spain

    José María Limiñana Cañal

Authors
  1. Otilia Evora Santana Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María Luisa Malé Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Juan Francisco Hernández Santana
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José María Limiñana Cañal
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Antonio Manuel Martín Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rodríguez, O.E.S., Malé Gil, M.L., Santana, J.F.H. et al. Prevalence of serologic markers of HBV, HDV, HCV and HIV in non-injection drug users compared to injection drug users in Gran Canaria, Spain. Eur J Epidemiol 14, 555–561 (1998). https://doi.org/10.1023/A:1007410707801

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007410707801

Search

Navigation